In EMPEROR-Preserved (n = 5,792; median follow-up 26.2 months), empagliflozin reduced heart failure hospitalizations from 11.1% to 8.3% and cardiovascular mortality from 16.2% to 13.4% (hazard ratio (HR) 0.75; 95% confidence interval (CI) 0.68-0.84). In a multi-agent trial (n = 1,253; 18 months), SGLT2 inhibitors lowered cardiovascular mortality (4% vs. 5%) and HF hospitalizations (7% vs. 10%), with an absolute risk reduction of 1% and 3%, respectively, and improved patient-reported quality of life (mean Kansas City Cardiomyopathy Questionnaire (KCCQ) score increase of 8 points). The gene discussed is SLC5A2; the disease is heart failure.